Malaghan Institute (@malaghan_inst) 's Twitter Profile
Malaghan Institute

@malaghan_inst

#NZ's world-class independent #biomedicalresearch institute, focusing on breakthrough discoveries in #immunology and #immunotherapy. Charity Reg. CC 10357

ID: 442319627

linkhttp://www.malaghan.org.nz calendar_today21-12-2011 00:29:16

1,1K Tweet

1,1K Followers

736 Following

Current Protocols (@curr_protocols) 's Twitter Profile Photo

Learn how to make mRNA vaccines from mRNA synthesis to encapsulation in ionizable lipid nanoparticles. This protocol-based article is published in Cytometry! Ferrier Research Institute, Malaghan Institute …rentprotocols.onlinelibrary.wiley.com/doi/full/10.10…

The Conversation - Australia + New Zealand (@conversationedu) 's Twitter Profile Photo

COVID proved the therapeutic potential of RNA technology – making it more available is the next goal. Now a new manufacturing protocol will help researchers to advance the technology. Malaghan Institute theconversation.com/covid-proved-t…

Robert Weinkove (@robweinkove) 's Twitter Profile Photo

Great to have Professor Carl June Carl June join the Board of local CAR T-cell startup, BioOra. Stay tuned for further ENABLE (NCT04049513) clinical trial announcements! Malaghan Institute

Robert Weinkove (@robweinkove) 's Twitter Profile Photo

CD28 CAR T cells without the neurotoxicity? Delighted to announce that dose escalation trial results of anti-CD19 CAR T cells combining CD28 & TLR2 co-stimulation (“WZTL-002”) have been accepted for oral presentation at #ASH2023 next month! Abstract #890. Malaghan Institute BioOra

Malaghan Institute (@malaghan_inst) 's Twitter Profile Photo

NZ’s first trial of a novel CAR T-cell therapy has shown the promise of being safer than leading commercial CAR T-cell products in treating certain types of blood cancer, while remaining effective fabio galante malaghan.org.nz/news-and-repor…

Imperial Department of Infectious Disease (@imperialinfect) 's Twitter Profile Photo

Join us for our next Infection and Immunity Seminar with Jordan Minnell Malaghan Institute. He will discuss mRNA vaccines against malaria tailored for liver-resident memory T cells. 🗓️7 Nov, 12:30 - 13:30 📍St. Mary's Campus/Online Find out more 👉 imperial.ac.uk/events/166150/…

Join us for our next Infection and Immunity Seminar with <a href="/Jminnell/">Jordan Minnell</a> <a href="/Malaghan_Inst/">Malaghan Institute</a>.

He will discuss mRNA vaccines against malaria tailored for liver-resident memory T cells.

🗓️7 Nov, 12:30 - 13:30
📍St. Mary's Campus/Online 

Find out more 👉 imperial.ac.uk/events/166150/…
RNZ Saturday Morning (@saturdayrnz) 's Twitter Profile Photo

"I wake up every morning and say I'm well. There was a time I didn't think I'd have a 2023, and now I can look forward to 2024" Carl June Malaghan Institute rnz.co.nz/national/progr…

Palli Thordarson (@pallithordarson) 's Twitter Profile Photo

Kjesten Wiig from Malaghan Institute Te Herenga Waka—Victoria University of Wellington is the co-Director of the New Zealand RNA Technology Development Platform. Fantastic presentation here about NZ RNA capabilities and programs here at the NZ Controlled Release Society (NZCRS) meeting University of Otago #RNA #mRNA

Kjesten Wiig from <a href="/Malaghan_Inst/">Malaghan Institute</a> <a href="/VicUniWgtn/">Te Herenga Waka—Victoria University of Wellington</a>  is the co-Director of the New Zealand RNA Technology Development Platform. Fantastic presentation here about NZ RNA capabilities and programs here at the NZ Controlled Release Society (NZCRS) meeting <a href="/otago/">University of Otago</a> #RNA #mRNA
The Conversation - Australia + New Zealand (@conversationedu) 's Twitter Profile Photo

COVID proved the therapeutic potential of RNA technology – making it more available is the next goal. Now a new manufacturing protocol will help researchers to advance the technology. Malaghan Institute theconversation.com/covid-proved-t…

Robert Weinkove (@robweinkove) 's Twitter Profile Photo

Anti-CD19 CAR T without the neurotoxicity? Excited to deliver an oral presentation of phase 1 ENABLE trial results at #ASH23 today (3pm, Hall 6A, abstract 0890). #malaghan_inst

Anti-CD19 CAR T without the neurotoxicity? Excited to deliver an oral presentation of phase 1 ENABLE trial results at #ASH23 today (3pm, Hall 6A, abstract 0890). #malaghan_inst
Judith Collins (@judithcollinsmp) 's Twitter Profile Photo

Lovely to be able to celebrate the remarkable service of Graham Malaghan as Chair of Malaghan Institute for 35 years. Malaghans leading scientific research is another great news story for New Zealand.

Lovely to be able to celebrate the remarkable service of Graham Malaghan as Chair of <a href="/Malaghan_Inst/">Malaghan Institute</a> for 35 years. 
Malaghans leading scientific research is another great news story for New Zealand.
Kerry Hilligan (@kerryhilligan) 's Twitter Profile Photo

📢 Bacterial-induced or passively administered IFNg protects against #COVID19 in 🐭 by arming the 🫁 epithelium with viral restriction factors. Check out our new paper in Nature Communications here: nature.com/articles/s4146… Summary from NIAID News below 👇

Blood Cancers Today (@blood_cancers) 's Twitter Profile Photo

The first human trial of novel anti-CD19 CAR T-Cell therapy shows promising phase I outcomes in patients with B-cell non-Hodgkin lymphoma. Read more about the trial, led by Robert Weinkove of Malaghan Institute. #ASH23 📰 buff.ly/3GW2D0A

The first human trial of novel anti-CD19 CAR T-Cell therapy shows promising phase I outcomes in patients with B-cell non-Hodgkin lymphoma.

Read more about the trial, led by <a href="/robweinkove/">Robert Weinkove</a> of <a href="/Malaghan_Inst/">Malaghan Institute</a>. #ASH23

📰 buff.ly/3GW2D0A
Farah (@kiwifarah) 's Twitter Profile Photo

My finest work: One school of thought is there might be an infection sweet-spot, where just the right number of hookworms hanging out in your intestine, cruising for sex & sucking your blood, might be an infection with benefits for both host & hookworms. rnz.co.nz/news/in-depth/…

Ashraful Haque (@drashhaque) 's Twitter Profile Photo

Moderna and Pfizer Inc. mRNA vaccines protected against severe COVID19. Similar tech could protect against #malaria. Register for #APVIC2024 (14-17 May, Marvel Stadium) apvic.org to learn from Prof Ian Hermans Malaghan Institute Here's the paper doi.org/10.1038/s41590…

<a href="/moderna_tx/">Moderna</a> and <a href="/pfizer/">Pfizer Inc.</a> mRNA vaccines protected against severe COVID19. Similar tech could protect against #malaria. Register for #APVIC2024 (14-17 May, Marvel Stadium) apvic.org to learn from Prof Ian Hermans <a href="/Malaghan_Inst/">Malaghan Institute</a> Here's the paper doi.org/10.1038/s41590…
International Union of Immunological Societies (@iuis_online) 's Twitter Profile Photo

This year's International Day of Immunology will be Monday, April 29th! This year's theme is #ImmunityAndAging! Register for our #DayofImmunology webinar at 14 CEST: loom.ly/M63fa6w Check out our previous #DayofImmunology webinars here: loom.ly/2L-Vo74

This year's International Day of Immunology will be Monday, April 29th! This year's theme is #ImmunityAndAging!

Register for our #DayofImmunology webinar at 14 CEST: loom.ly/M63fa6w 

Check out our previous #DayofImmunology webinars here: loom.ly/2L-Vo74
The Conversation - Australia + New Zealand (@conversationedu) 's Twitter Profile Photo

COVID proved the therapeutic potential of RNA technology – making it more available is the next goal. Now a new manufacturing protocol will help researchers to advance the technology. Malaghan Institute theconversation.com/covid-proved-t…

Blood Cancers Today (@blood_cancers) 's Twitter Profile Photo

WZTL-002 showed low rates of toxicities and elicited CRs comparable to commercially available second-generation CAR T-cell agents in patients with R/R B-cell non-Hodgkin lymphomas. Read more from the trial led by Robert Weinkove of Malaghan Institute. ➡️ buff.ly/3BDwoV8

WZTL-002 showed low rates of toxicities and elicited CRs comparable to commercially available second-generation CAR T-cell agents in patients with R/R B-cell non-Hodgkin lymphomas.

Read more from the trial led by <a href="/robweinkove/">Robert Weinkove</a> of <a href="/Malaghan_Inst/">Malaghan Institute</a>.

➡️ buff.ly/3BDwoV8